Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An HIV prevention roundup
“All insurers failing to offer PrEP without cost sharing beginning in January 2021 are clearly not following the law.”
Globally, a child contracts HIV every 100 seconds. A new, affordable treatment is available, but the COVID-19 pandemic hinders access.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
The global supply of tenofovir and six other important generic drugs must be ensured, warns a UNAIDS analysis.
Fact-checkers and HIV advocates break down the president’s State of the Union boasts.
A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.
“This is excellent news for all children living with HIV.”
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.
U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.